Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
MOORESTOWN, N.J. , March 10, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication Risk Stratification and Medication Risk Mitigation Matrix® suite of decision support tools, elected Dennis K. Helling, PharmD, ScD (Hon), FCCP, FASHP, FAPhA, to its Board of Directors at the firm’s meeting held March 8, 2017.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/60485f75-51b8-492c-9ef8-7284084e69b6
|
|||||
Dr. Helling is the Executive Director Emeritus, Pharmacy Operations & Therapeutics, Kaiser Permanente Colorado, and Clinical Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Helling served Kaiser from 1992 – 2013.
“TRHC is delighted to welcome Dr. Helling to the Board of Directors,” said Calvin H. Knowlton, PhD, TRHC Chairman and CEO. “He brings to our company outstanding credentials, experience, innovation and leadership in the pharmacy industry generally, and the emerging role of pharmacists in healthcare and personalized medication therapy management, specifically. He joins our company as we emerge as a leader in medication safety. We appreciate Dr. Helling’s willingness to serve as a director and look forward to benefitting from his judgment and counsel.”
Dr. Helling was a Founding Member and President of the American College of Clinical Pharmacy. He also served as President of the Accreditation Council for Pharmacy Education and the American Pharmacists Association Foundation. Currently, he is the Vice President of The Denver Hospice Board of Directors and Chairman of the Working Group on Pharmacy Reimbursement in the Federation of International Pharmacy.
Dr. Helling’s practice emphasis and research have been focused on documenting the impact pharmacists have on improving patient and economic outcomes. A frequent lecturer nationally and internationally, Dr. Helling was the 2013 American Pharmacist Association’s Remington Honor Medalist, the profession’s highest recognition. A graduate of the St. Louis College of Pharmacy (BS Pharm), University of Cincinnati College of Pharmacy (PharmD), Dr. Helling completed a clinical/hospital pharmacy Residency at Cincinnati General Hospital. He also completed the Kaiser Permanente Executive Program, Stanford University School of Business.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to personalize and optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. For more information, please visit: www.trhc.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]
